Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2021

Open Access 01-01-2021 | Positron Emission Tomography | Review Article

Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives

Authors: Antonia Dimitrakopoulou-Strauss, Leyun Pan, Christos Sachpekidis

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2021

Login to get access

Abstract

Dynamic PET (dPET) studies have been used until now primarily within research purposes. Although it is generally accepted that the information provided by dPET is superior to that of conventional static PET acquisitions acquired usually 60 min post injection of the radiotracer, the duration of dynamic protocols, the limited axial field of view (FOV) of current generation clinical PET systems covering a relatively small axial extent of the human body for a dynamic measurement, and the complexity of data evaluation have hampered its implementation into clinical routine. However, the development of new-generation PET/CT scanners with an extended FOV as well as of more sophisticated evaluation software packages that offer better segmentation algorithms, automatic retrieval of the arterial input function, and automatic calculation of parametric imaging, in combination with dedicated shorter dynamic protocols, will facilitate the wider use of dPET. This is expected to aid in oncological diagnostics and therapy assessment. The aim of this review is to present some general considerations about dPET analysis in oncology by means of kinetic modeling, based on compartmental and noncompartmental approaches, and parametric imaging. Moreover, the current clinical applications and future perspectives of the modality are outlined.
Literature
1.
Phelps ME, Hoffmann EJ, Na M, Ter-Pogossian MM. Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med. 1975;16:210–24.PubMed
2.
Sokoloff L, Reivich M, Kennedy C, et al. The (14C) deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anerstized albino rat. J Neurochem. 1977;28:897–916.PubMed
3.
Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-glucose: validation of methos. Ann Neurol. 1979;6:371–88.PubMed
4.
Wienhard K. measurements of glucose consumption using (18F)fluorodeoxyglucose. Methods. 2002;27:218–25.PubMed
5.
Tomasi G, Turkheimer F, Aboagye E. importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol. 2012;4:131–46.
6.
Badawi RD, Shi H, Hu P, et al. First human imaging studies with the EXPLORER Total-body PET scanner. J Nucl Med. 2019;60:299–303.PubMedPubMedCentral
7.
van Sluis J, Boellaard R, Dierckx RA, Stormezand G, Glaudemans AWJM, Noordzij W. Image quality and activity optimization in oncological 18F-FDG PET using the digital biograph vision PET/CT. J Nucl Med. 2019;jnumed.119.234351
8.
Pantel AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, Muehllehner G, Parma MJ, et al. PennPET explorer: human imaging on a whole-body imager. J Nucl med. 2020;61(1):144–51.PubMedPubMedCentral
9.
Karp JS, Viswanath V, Geagan MJ, Muehllehner G, Pantel AR, Parma MJ, et al. PennPET explorer: design and preliminary performance of a whole-body imager. J Nucl med. 2020;61(1):136–43.PubMedPubMedCentral
10.
Zhang X, Xie Z, Berg E, Judenhofer MS, Liu W, Xu T, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl med. 2020;61:285–91.PubMed
11.
Karakatsanis, NA, Lodge MA, Zhou Y, Mhlanga J, Chaudhry MA, Tahari AK, et al. 2011, October. Dynamic multi-bed FDG PET imaging: feasibility and optimization. In 2011 IEEE nuclear science symposium conference record, pp. 3863–3870.
12.
Karakatsanis NA, Lodge MA, Tahari AK, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: I. concept, acquisition protocol optimization and clinical application. Phys Med Biol. 2013;58(20):7391.PubMedPubMedCentral
13.
Karakatsanis NA, Lodge MA, Zhou Y, Wahl RL, Rahmim A. Dynamic whole-body PET parametric imaging: II. Task-oriented statistical estimation. Phys Med Biol. 2013;58(20):7419.PubMedPubMedCentral
14.
Fahrni G, Karakatsanis NA, Di Domenicantonio G, Garibotto V, Zaidi H. Does whole-body Patlak 18 F-FDG PET imaging improve lesion detectability in clinical oncology? Eur Radiol. 2019;29(9):4812–21.PubMed
15.
Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, et al. Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging. 2019;46:501–18.PubMed
16.
Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, et al. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1288–99.PubMed
17.
Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U. Dimitrakopoulou-Strauss a. comparison of the pharmacokinetics of 68Ga-DOTATOC and (18F)FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115–20.PubMed
18.
Graham MM, Lewellen BL. High-speed automated discrete blood sampling for positron emission tomography. J Nucl Med. 1993;34:1357–60.PubMed
19.
Kanno I, Iida H, Miura S, Murakami M, Takahashi K, Sasaki H, et al. A system for cerebral blood flow measurement using an H215O autoradiographic method and positron emission tomography. J Cerebr Blood Flow Metab. 1987;7:143–53.
20.
van den Hoff J, Burchert W, Müller-Schauenburg W, Meyer GJ, Hundeshagen H. accurate local blood flow measurements with dynamic PET: fast determination of input function delay and dispersion by multilinear minimization. J Nucl Med. 1993;34:1770–7.PubMed
21.
22.
Turgeon V, Kertzscher G, Carroll L, Hopewell R, Massarweh G, Enger SA. Characterization of scintillating fibers for use as positron detector in positron emission tomography. Phys Med. 2019;65:114–20.PubMed
23.
Ohtake T, Kosaka N, Watanabe T, Yokoyama I, Moritan T, Masuo M, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432–8.PubMed
24.
Miyazawa H, Osmont A, Petit-Taboue MC, Tillet I, Travere JM, Young AR, et al. Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263–72.PubMed
25.
Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L, editors. The metabolism of the human brain studied with positron emission tomography. New York: Raven press; 1983. p. 123–48.
26.
Feng ST, Cui M, Gao J, Wu B, Sha W, Huang B. Image-derived arterial input function in dynamic positron emission tomography-computed tomography: a method using both positron emission tomographic and computed tomographic images. J Comput AssistTomogr. 2012;36:762–7.
27.
28.
Naganawa M, Gallezot J-D, Shah V, et al. Assessment of population-based input functions for the Patlak plot using whole body 18F-FDG PET imaging. J Nucl Med. 2019;60(Suppl. 1):519.
29.
Rissanen E, Tuisku J, Luoto P, Arponen E, Johansson J, Oikonen V, et al. Automated reference region extraction and population-based input function for brain ((11C))TMSX PET image analyses. J Cereb Blood Flow Metab. 2015;35:157–65.PubMed
30.
O’Sullivan F, Kirrane J, Muzi M, O’Sullivan JN, Spence AM, Mankoff DA, et al. Kinetic quantitation of cerebral PET-FDG studies withour concurrent blood sampling: statistical recovery of the arterial input function. IEEE Trans Med Imaging. 2010;29:610–24.PubMed
31.
Reivich M, Alavi A, Wolf A, Fowler J, Russell J, Arnett C, et al. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for (18F)Fluorodeoxyglucose and (11C)Deoxyglucose. J Cereb Blood Flow Metab. 1985;5:179–92.PubMed
32.
Hasselbalch SG, Madsen PL, Knudsen GM, Holm S, Paulson OB. Calculation of the FDG lumped constant by simultaneous measurements of global glucose and FDG metabolism in humans. J Cereb Blood Flow Metab. 1998;18:154–60.PubMed
33.
Strauss LG, Koczan D, Klippel S, Pan L, Cheng C, Willis S, et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med. 2008;49:1238–44.PubMed
34.
Strauss LG, Koczan D, Klippel S, Pan L, Cheng C, Haberkorn U, et al. Impact of cell-proliferation-associated gene expression on 2-deoxy-2-((18)f)fluoro-D-glucose (FDG) kinetics as measured by dynamic positron emission tomography (dPET) in colorectal tumors. Mol imaging biol. 2011;13:1290–300.PubMed
35.
Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818–23.PubMed
36.
Pan L, Mikolajczyk K, Strauss L, Haberkorn U. Dimitrakopoulou-Strauss a. machine learning based parameter imaging and kinetic modeling of PET data. J Nucl Med. 2007;48:158P.
37.
Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS, et al. Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse. 1999;34:290–304.PubMed
38.
Muzi M, O’Sullivan F, Mankoff D, Doot R, Pierce L, Kurland B, et al. QIN: quantitative assessment of dynamic PET imaging data in cancer imaging. Magn Reson Imaging. 2013;30:1203–15.
39.
Shields AF, Briston DA, Chandupatla S, Douglas KA, Lawhorn-Crews J, Collins JM, et al. A simplified analysis of (18F)3-deoxy-3-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32:1269–75.PubMed
40.
Burger C, Buck A. Tracer kinetic modellingo of receptor data with mathematical metabolite correction. Eur J Nucl Med. 1996;23:539–45.PubMed
41.
Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. NeuroImage. 1996;4:153–8.PubMed
42.
Cunningham VJ, Hume SP, Price GR, Ahler RG, Cremer JE, Jones AK. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J Cereb Blood Flow Metab. 1991;11:1–9.PubMed
43.
Kotasidis FA, Tsoumpas C, Rahmin A. Advanced kinetic modelling strategies: towards adoption in clinical PET imaging. Clin Transl Imaging. 2014;2:219–37.
44.
Patlak CS, Blasberg RG. Graphical evaluationof blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Flow Metab. 1985;5:584–90.
45.
Karakatsanis NA, Zhou Y, Lodge MA, Casey ME, Wahl RL, Zaidi H, et al. Generalized whole-body Patlak parametric imaging for enhanced quantification in clinical use. Phys Med Biol. 2015;60:8643–73.PubMedPubMedCentral
46.
Karakatsanis NA, Casey ME, Lodge MA, Rahmin A, Zaidi H. Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation-maximization reconstruction. Phys Med Biol. 2016;61:5456–85.PubMedPubMedCentral
47.
Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen C-T, et al. Lung cancer—a fractal viewpoint. Nat Rev Clin Oncol. 2015;12:664–75.PubMedPubMedCentral
48.
Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Mikolajczyk K, Lehnert T, Bernd L, et al. On the fractal nature of positron emission tomography (PET) studies. World J Nucl Med. 2003;4:306–13.
49.
Breki CM, Dimitrakopoulou-Strauss A, Hassel J, Theoharis T, Sachpekidis C, Pan L, et al. Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Res. 2016;6:61.PubMedPubMedCentral
50.
Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metast ases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr. 1992;16:684–9.PubMed
51.
Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform. 1998;23:207–14.
52.
Strauss LG. Dimitrakopoulou-Strauss a, Koczan D, Bernd l, Haberkorn U, Ewerbeck V et al. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med. 2004;45:1528–35.PubMed
53.
Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, et al. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-(F-18)-fluoro-D-glucose positron emission tomography: a feasibility study. Mol Imaging Biol. 2007;9:308–17.PubMed
54.
Karakatsanis NA, Lodge MA, Casey ME, Zaidi H, Rahmim A. Impact of acquisition time-window on clinical whole-body PET parametric imaging. In 2014 IEEE nuclear science symposium and medical imaging conference (NSS/MIC), 2014;pp. 1–8.
55.
Zhu W, Li Q, Bai B, Conti PS, Leahy RM. Patlak image estimation from dual time-point list-mode PET data. IEEE Trans Med Imaging. 2014;33:913–924.A.PubMedPubMedCentral
56.
Zhuang M, Karakatsanis NA, Dierckx RA, Zaidi H. Quantitative analysis of heterogeneous [18 F] FDG static (SUV) vs. Patlak (Ki) whole-body PET imaging using different segmentation methods: a simulation study. Mol Imaging Biol. 2019;21(2):317–27.PubMed
57.
Thireou T, Strauss LG, Dimitrakopoulou-Strauss A, Kontaxakis G, Pavlopoulos S, Santos A. Performance evaluation of principal component analysis in dynamic FDG-PET studies of recurrent colorectal cancer. Comput Med Imaging Graph. 2003;27(1):43–51.PubMed
58.
Pedersen F, Bergström M. Bengtsson, Langström B. principal component analysis of dynamic positron emission tomography images. Eur J Nucl Med. 1994;21:1285–92.PubMed
59.
Thireou T, Kontaxakis G, Strauss LG, Dimitrakopoulou-Strauss A, Pavlopoulos S, Santos A. Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images. Med Biol Eng Comput. 2005;43(1):23–32.PubMed
60.
Dimitrakopoulou-Strauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Future Oncol. 2015;5:127–42.
61.
Dimitrakopoulou-Strauss A, Pan L, Strauss LG. Quantitative approaches of dynamic FDG-PET and PET/CT studies (dPET/CT) for the evaluation of oncological patients. Cancer Imaging. 2012;12:283–9.PubMedPubMedCentral
62.
Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, et al. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med. 2002;43:510–8.PubMed
63.
Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, et al. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med. 2001;42:713–20.PubMed
64.
Rusten E, Rødal J, Revheim ME, Skretting A, Bruland OS, Malinen E. Quantitative dynamic 18FDG-PET and tracer kinetic analysis of soft tissue sarcomas. Acta Oncol. 2013;52(6):1160–7.PubMed
65.
Dimitrakopoulou-Strauss A, Hohenberger P, Pan L, Kasper B, Roumia S, Strauss LG. Dynamic PET with FDG in patients with unresectable aggressive fibromatosis: regression-based parametric images and correlation to the FDG kinetics based on a 2-tissue compartment model. Clin Nucl Med. 2012;37:943–8.PubMed
66.
Strauss LG, Strauss LG, Klippel S, Pan L, Schönleben K, Haberkorn U, et al. Assessment of quantitative FDG PET data in primary colorectal tumours: which parameters are important with respect to tumour detection? Eur J Nucl Med Mol Imaging. 2007;34:868–77.PubMed
67.
68.
Mullani NA, Herbst RS, O’Neil R, Gould KL, Barron BJ, Abbruzzese JL. Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: a comparison with 15O-labeled water-measured blood flow. J Nucl Med. 2008;49:517–23.PubMed
69.
Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, et al. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors. J Nucl Med. 2012;53:512–20.PubMed
70.
Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A. 68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. Am J Nucl Med Mol Imaging. 2018;8:351–9.PubMedPubMedCentral
71.
Dimitrakopoulou-Strauss A. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Cancer Immunol Immunother. 2019;68:813–22.PubMed
72.
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using (18F)-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET study group. Eur J Cancer. 1999;35:1773–82.PubMed
73.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.PubMedPubMedCentral
74.
Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Rühl A, Irngartinger G, Stremmel W, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med. 2004;45:1480–7.PubMed
75.
Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med. 2010;51:551–8.PubMed
76.
Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging. 2010;37:1481–9.PubMed
77.
Sachpekidis C, Karampinis I, Jakob J, Kasper B, Nowak K, Pilz L, et al. Neoadjuvant pazopanib treatment in high-risk soft tissue sarcoma: a quantitative dynamic 18F-FDG PET/CT study of the german interdisciplinary sarcoma group. Cancers. 2019;11:E790.PubMed
78.
Scarpelli M, Simoncic U, Perlman S, Liu G, Jeraj R. Dynamic 18F-FLT imaging of spatiotemporal changes in tumor cell proliferation and vasculature reveals the mechanistic actions of anti-angiogenic therapy. Phys Med Biol. 2018;63:155008.PubMed
79.
Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Charlop A, Lawton TJ, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002;43:500–9.PubMed
80.
Humbert O, Lasserre M, Bertaut A, Fumoleau P, Coutant A, Brunotte F, et al. Breast cancer blood flow and metabolism on dual-acquisition 18F-FDG PET: correlation with tumor phenotype and neoadjuvant chemotherapy response. J Nucl Med. 2018;59:1035–41.PubMed
81.
Bahce I, Yaqub M, Errami H, Schuit RC, Schober P, Thunnissen E, et al. Effects of erlotinib therapy on (11C)erlotinib uptake in EGFR mutated, advanced NSCLC. EJNMMI Res. 2016;6:10.PubMedPubMedCentral
82.
Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. 18F-FLT and 18F-FDOPA PET kinetics in recurrent braiun tumors. Eur J Nucl Med Mol Imaging. 2014;41:1199–209.PubMedPubMedCentral
83.
Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34(9):576–84.PubMed
84.
Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, et al. Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myelomapatients undergoing high-dose chemotherapy and autologous stem cell transplantation. Eur J Nucl med Mol imaging. 2017;44(1):50–62.PubMed
85.
Sachpekidis C, Anwar H, Winkler JK, Kopp-Schneider A, Larribere L, Haberkorn U, et al. Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunol Immunother. 2018;67:1261–70.PubMed
86.
Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376–83.PubMed
87.
Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, et al. The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289–96.PubMed
88.
Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM. Blackford a, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017 Sep;58(9):1421–8.PubMedPubMedCentral
89.
Lammertsma AA, Hume SP. Simplified reference tissue mode for PET receptor studies. Neuroimage. 1996;4:153–8.PubMed
90.
Hillmer AT, Esterlis I, Gallezot JD. bois F, Zheng MQ, Nabulsi N, et al. Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (−)-(18F)Flubatine PET: implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. Neuroimage. 2016;141:71–80.PubMedPubMedCentral
91.
Ichise M, Liow JS, Lu JQ, Takano A, Model K, Toyama H, et al. Linearized reference tissue parametric imaging methods: application to (11C)DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab. 2003;23:1096–112.PubMed
92.
Raichle ME, Martin WRW, Herscovitch P, Mintun MA, Markham J. Brain blood flow measured with intravenous H2O15. II. Implementation and validation. J Nucl Med. 1983;24:790–8.PubMed
93.
Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octeotride kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.PubMed
94.
Ilan E, Sandström M, Velikyan I, Sundin A, Eriksson B, Lubberink M. Parametric net imflux rate images of 68Ga-DOTATOC and 68Ga-DOTATATE: quantitative accuracy and improved image contrast. J Nucl Med. 2017;58:744–9.PubMed
95.
96.
Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, et al. Multiple time-point 68Ga-PSMA I&T PET/CT for characterization of primary prostate Cancer: value of early dynamic and delayed imaging. Clin Nucl Med. 2017;42:286–93.
97.
Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Mäcke HR, Eisenhut M, Strauss LG. 68Ga-labeled Bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG. J Nucl Med. 2007;48:1245–50.PubMed
98.
Dimitrakopoulou-Strauss A, Seiz M, Tuettenberg J, Schmieder K, Eisenhut M, Haberkorn U, et al. Pharmacokinetic studies of 68Ga-labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in patients with recurrent gliomas and comparison to grading. Clin Nucl Med. 2011;36:101–8.PubMed
99.
Koopman T, Verburg N, Pouwels PJ, Wesseling P, Hoekstra OS, De Witt Hamer PC, et al. Quantitative parametric maps of O-(2-(18F)fluoroethyl)-L-tyrosine kinetics in diffuse gliomas. J Cereb Blood Flow Metab. 2019; may 24:271678X19851878
100.
Kudomi N, Maeda Y, Hatakeyama T, Yamamoto Y, Nishiyama Y. Fully parametric imaging with reversible tracer 18F-FLT within a reasonable time. Radiol Phys Technol. 2017;10:41–8.PubMed
101.
Sachpekidis C, Thieke C, Askoxylakis V, Nicolay NH, Huber PE, Thomas M, et al. Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am J Nucl Med Mol Imaging. 2015;5(2):127–42.PubMedPubMedCentral
102.
Schwartz J, Grkovski M, Rimner A, Schroeder H, Zanzonico PB, Carlin SD, et al. Pharmacokinetic analysis of dynamic 18F-Fluoromisonidazole PET data in non-small cell lung cancer. J Nucl Med. 2017;58:911–9.PubMedPubMedCentral
103.
Grkovski M, Lee NY, Schroeder H, Carlin SD, Beattie BJ, Riaz N, et al. Monitoring early response to chemoradiotherapy with 18F-MISO dynamic PET in head and neck cancer. Eur J Nucl Med Mol Imaging. 2017;44:1682–91.PubMedPubMedCentral
104.
105.
Verwer EE, Zegers CM, van Elmpt W, Wierts R, Windhorst AD, Mottaghy FM, et al. Pharmacokinetic modeling of a novel hypoxia PET tracer (18F)HX4 in patients with non-small cell lung cancer. EJNMMI Phys. 2016;3(1):30.PubMedPubMedCentral
106.
Strauss LG, Pan L, Cheng C, Haberkorn U. Dimitrakopoulou-Strauss A. Shortened acquisition protocols for the quantitative assessment of the 2-tissue-compartment model using dynamic PET/CT 18F-FDG studies. J Nucl Med. 2011;52:379–85.PubMed
107.
Van Sluis J, de Jong J, Schaar J, Noordzij W, van Snick P, Dierckx R, et al. Performance characteristics of the digital biograph vision PET/CT system. J Nucl Med. 2019;60:1031–6.PubMed
108.
Zein SA, Karakatsanis NA, Issa M, Haj-Ali AA, Nehmeh SA. Physical performance of a long axial field of view PET scanner prototype with sparse rings configuration: a Monte Carlo simulation study. Med Phys. 2020. https://​doi.​org/​10.​1002/​mp.​14046.
Metadata
Title
Kinetic modeling and parametric imaging with dynamic PET for oncological applications: general considerations, current clinical applications, and future perspectives
Authors
Antonia Dimitrakopoulou-Strauss
Leyun Pan
Christos Sachpekidis
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-020-04843-6

Other articles of this Issue 1/2021

European Journal of Nuclear Medicine and Molecular Imaging 1/2021 Go to the issue

Image of the Month

[68Ga]Ga-DOTA-TOC PET/CT fused to MRI in post-operative evaluation of olfactory groove meningioma: a case on millimetric remnants

Correction

Correction to: Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma

Original Article

A microdose clinical trial to evaluate [18F]Florastamin as a positron emission tomography imaging agent in patients with prostate cancer

Review Article

The value of 18F-FDG PET/CT for the diagnosis of device-related infections in patients with a left ventricular assist device: a systematic review and meta-analysis

Image of the Month

First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT

Image of the Month

18F-FDG PET/CT of multiple cavitating pulmonary squamous cell carcinoma